|
US2940972A
(en)
|
1957-06-27 |
1960-06-14 |
Thomae Gmbh Dr K |
Tri-and tetra-substituted pteridine derivatives
|
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
|
GB9125001D0
(en)
|
1991-11-25 |
1992-01-22 |
Ici Plc |
Heterocyclic compounds
|
|
EP0763537A3
(en)
|
1993-05-14 |
1997-10-22 |
Genentech Inc |
Non-peptides farnesyl transfer inhibitors
|
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
|
WO1998004689A1
(en)
|
1995-07-31 |
1998-02-05 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
|
TW472045B
(en)
|
1996-09-25 |
2002-01-11 |
Astra Ab |
Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
|
|
EP1001945B1
(en)
|
1997-05-28 |
2011-03-02 |
Aventis Pharmaceuticals Inc. |
QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES
|
|
US6235740B1
(en)
|
1997-08-25 |
2001-05-22 |
Bristol-Myers Squibb Co. |
Imidazoquinoxaline protein tyrosine kinase inhibitors
|
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
|
JP2002534512A
(ja)
|
1999-01-15 |
2002-10-15 |
ノボ ノルディスク アクティーゼルスカブ |
非ペプチドｇｌｐ−１アゴニスト
|
|
BR0013952A
(pt)
|
1999-09-15 |
2002-05-14 |
Warner Lambert Co |
Pteridinonas como inibidores de cinase
|
|
DE10013318A1
(de)
|
2000-03-17 |
2001-09-20 |
Merck Patent Gmbh |
Formulierung enthaltend Chinoxalinderivate
|
|
WO2002076985A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
DE60223720T2
(de)
|
2001-12-18 |
2008-10-30 |
Merck & Co., Inc. |
Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5
|
|
US7402585B2
(en)
|
2001-12-24 |
2008-07-22 |
Astrazeneca Ab |
Substituted quinazoline derivatives as inhibitors of aurora kinases
|
|
JP2003213463A
(ja)
|
2002-01-17 |
2003-07-30 |
Sumitomo Chem Co Ltd |
金属腐食防止剤および洗浄液
|
|
EP1496896A4
(en)
|
2002-04-08 |
2007-10-31 |
Merck & Co Inc |
AKT INHIBITORS EFFECT
|
|
US7265378B2
(en)
|
2002-07-10 |
2007-09-04 |
E. I. Du Pont De Nemours And Company |
Electronic devices made with electron transport and/or anti-quenching layers
|
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
|
KR20110050745A
(ko)
|
2002-10-03 |
2011-05-16 |
탈자진 인코포레이티드 |
혈관항상성 유지제 및 그의 사용 방법
|
|
AR043059A1
(es)
|
2002-11-12 |
2005-07-13 |
Bayer Pharmaceuticals Corp |
Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
|
|
US7098332B2
(en)
|
2002-12-20 |
2006-08-29 |
Hoffmann-La Roche Inc. |
5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
|
|
EP1590341B1
(en)
|
2003-01-17 |
2009-06-17 |
Warner-Lambert Company LLC |
2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
|
|
EP1620413A2
(en)
|
2003-04-30 |
2006-02-01 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
|
JP4847868B2
(ja)
|
2003-05-14 |
2011-12-28 |
ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド |
化合物、及び、アミロイドベータの調節におけるその使用
|
|
HRP20090036T3
(en)
|
2003-05-23 |
2009-03-31 |
Æterna Zentaris Gmbh |
Novel pyridopyrazines and use thereof as kinase modulators
|
|
DE10323345A1
(de)
|
2003-05-23 |
2004-12-16 |
Zentaris Gmbh |
Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
|
|
WO2005007099A2
(en)
|
2003-07-10 |
2005-01-27 |
Imclone Systems Incorporated |
Pkb inhibitors as anti-tumor agents
|
|
AU2004259000A1
(en)
|
2003-07-21 |
2005-02-03 |
Bethesda Pharmaceuticals, Inc. |
Design and synthesis of optimized ligands for PPAR
|
|
US7511145B2
(en)
|
2003-08-01 |
2009-03-31 |
Genelabs Technologies, Inc. |
Bicyclic heteroaryl derivatives
|
|
PT1673092E
(pt)
|
2003-10-17 |
2007-11-23 |
4 Aza Ip Nv |
''derivados de pteridina substituídos com heterociclos e sua utilização em terapia''
|
|
MXPA06004194A
(es)
|
2003-11-07 |
2006-06-28 |
Chiron Corp |
Inhibicion de fgfr3 y tratamiento de mieloma multiple.
|
|
SG150533A1
(en)
|
2003-11-20 |
2009-03-30 |
Janssen Pharmaceutica Nv |
6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
|
|
AU2004295050A1
(en)
|
2003-11-24 |
2005-06-16 |
F.Hoffmann-La Roche Ag |
Pyrazolyl and imidazolyl pyrimidines
|
|
AU2004303602C1
(en)
|
2003-12-23 |
2009-05-28 |
Astex Therapeutics Limited |
Pyrazole derivatives as protein kinase modulators
|
|
US7205316B2
(en)
|
2004-05-12 |
2007-04-17 |
Abbott Laboratories |
Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
|
|
US7098222B2
(en)
|
2004-05-12 |
2006-08-29 |
Abbott Laboratories |
Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
|
|
US20090118261A1
(en)
|
2004-08-31 |
2009-05-07 |
Astrazeneca Ab |
Quinazolinone derivatives and their use as b-raf inhibitors
|
|
CN101039944B
(zh)
|
2004-10-14 |
2010-05-05 |
霍夫曼-拉罗奇有限公司 |
具有cdk1抗增殖活性的1,5-二氮杂萘唑烷酮类
|
|
WO2006040568A1
(en)
|
2004-10-15 |
2006-04-20 |
Astrazeneca Ab |
Quinoxalines as b raf inhibitors
|
|
DK1830869T3
(da)
|
2004-12-24 |
2013-08-26 |
Spinifex Pharm Pty Ltd |
Fremgangsmåde til behandling eller profylakse
|
|
JP2008530030A
(ja)
|
2005-02-14 |
2008-08-07 |
バイオノミックス リミテッド |
新規なチューブリン重合阻害剤
|
|
US9271963B2
(en)
|
2005-03-03 |
2016-03-01 |
Universitat Des Saarlandes |
Selective inhibitors of human corticosteroid synthases
|
|
CA2606017A1
(en)
|
2005-05-12 |
2006-11-23 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
CN101223170A
(zh)
|
2005-05-18 |
2008-07-16 |
惠氏公司 |
Tpl2激酶的4,6-二氨基-[1,7]萘啶-3-甲腈抑制剂以及其制备和使用方法
|
|
GB0513692D0
(en)
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
|
BRPI0615233A2
(pt)
|
2005-08-26 |
2011-05-10 |
Serono Lab |
derivados de pirazina e uso dos mesmos como inibidores p13k
|
|
EP1790342A1
(de)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
|
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
|
WO2007054556A1
(de)
|
2005-11-11 |
2007-05-18 |
Æterna Zentaris Gmbh |
Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
|
|
WO2007075567A1
(en)
|
2005-12-21 |
2007-07-05 |
Janssen Pharmaceutica, N.V. |
Triazolopyridazines as tyrosine kinase modulators
|
|
NO324350B1
(no)
*
|
2006-02-17 |
2007-09-24 |
Reslink As |
Generator for fluiddrevet produksjon av elektrisk energi og fremgangsmate for fremstilling av generatoren
|
|
CA2651072A1
(en)
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
|
GB0609621D0
(en)
|
2006-05-16 |
2006-06-21 |
Astrazeneca Ab |
Novel co-crystal
|
|
JP2009537590A
(ja)
|
2006-05-24 |
2009-10-29 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
四員複素環で置換された置換プテリジン
|
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
Novartis Ag |
吡咯并嘧啶化合物及其用途
|
|
EP2044027A2
(en)
|
2006-07-03 |
2009-04-08 |
Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg |
Fused bicyclic compounds interacting with the histamine h4 receptor
|
|
US8148361B2
(en)
|
2006-11-10 |
2012-04-03 |
Bristol-Myers Squibb Company |
Kinase inhibitors
|
|
JP2008127446A
(ja)
|
2006-11-20 |
2008-06-05 |
Canon Inc |
１，５−ナフチリジン化合物及び有機発光素子
|
|
CN102123712B
(zh)
|
2006-12-13 |
2014-03-19 |
默沙东公司 |
使用igf1r抑制剂治疗癌症的方法
|
|
CA2673736A1
(en)
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
AR064491A1
(es)
|
2006-12-22 |
2009-04-08 |
Astex Therapeutics Ltd |
Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr.
|
|
JP2010514693A
(ja)
|
2006-12-22 |
2010-05-06 |
ノバルティス アーゲー |
Ｐｄｋ１阻害のためのキナゾリン
|
|
KR20080062876A
(ko)
|
2006-12-29 |
2008-07-03 |
주식회사 대웅제약 |
신규한 항진균성 트리아졸 유도체
|
|
PE20090288A1
(es)
|
2007-05-10 |
2009-04-03 |
Smithkline Beecham Corp |
Derivados de quinoxalina como inhibidores de la pi3 quinasa
|
|
EP1990342A1
(en)
|
2007-05-10 |
2008-11-12 |
AEterna Zentaris GmbH |
Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
|
|
WO2008150827A1
(en)
|
2007-05-29 |
2008-12-11 |
Smithkline Beecham Corporation |
Naphthyridine, derivatives as p13 kinase inhibitors
|
|
AR066879A1
(es)
|
2007-06-08 |
2009-09-16 |
Novartis Ag |
Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
|
|
US8461209B2
(en)
|
2007-06-20 |
2013-06-11 |
Mitsubishi Tanabe Pharma Corporation |
Malonic acid sulfonamide derivative and pharmaceutical use thereof
|
|
JP5548123B2
(ja)
|
2007-06-21 |
2014-07-16 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
６−｛ジフルオロ［６−（１−メチル−１Ｈ−ピラゾル−４−イル）［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン−３−イル］メチル｝キノリンの多形および水和物の形態、塩、ならびに製造方法
|
|
WO2009009016A1
(en)
|
2007-07-06 |
2009-01-15 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
|
JP5298128B2
(ja)
*
|
2007-08-08 |
2013-09-25 |
グラクソスミスクライン エルエルシー |
癌の治療用のＩＧＦ−１Ｒ阻害剤としての２−［（２−｛フェニルアミノ｝−１Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）アミノ］ベンズアミド誘導体
|
|
WO2009019518A1
(en)
|
2007-08-09 |
2009-02-12 |
Astrazeneca Ab |
Pyrimidine compounds having a fgfr inhibitory effect
|
|
EP2173354A4
(en)
|
2007-08-09 |
2011-10-05 |
Glaxosmithkline Llc |
CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS
|
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
CN101910152B
(zh)
|
2007-11-16 |
2014-08-06 |
因塞特公司 |
作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺
|
|
JP2011519868A
(ja)
|
2008-05-05 |
2011-07-14 |
シェーリング コーポレイション |
癌を処置するための化学療法剤の連続投与
|
|
EP2282995B1
(en)
|
2008-05-23 |
2015-08-26 |
Novartis AG |
Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
|
|
EP2356116A1
(en)
|
2008-11-20 |
2011-08-17 |
OSI Pharmaceuticals, Inc. |
Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
|
|
WO2010084152A1
(en)
|
2009-01-21 |
2010-07-29 |
Basilea Pharmaceutica Ag |
Novel bicyclic antibiotics
|
|
WO2010088177A1
(en)
|
2009-02-02 |
2010-08-05 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
|
TW201041888A
(en)
|
2009-05-06 |
2010-12-01 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
MX364282B
(es)
|
2009-06-12 |
2019-04-22 |
Abivax |
Compuestos útiles para tratar envejecimiento prematuro y en particular progeria.
|
|
AU2010289397B2
(en)
|
2009-09-03 |
2016-05-26 |
Bioenergenix |
Heterocyclic compounds for the inhibition of PASK
|
|
JP5728683B2
(ja)
|
2009-09-04 |
2015-06-03 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
|
|
US20110123545A1
(en)
*
|
2009-11-24 |
2011-05-26 |
Bristol-Myers Squibb Company |
Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
|
|
EP2332939A1
(en)
|
2009-11-26 |
2011-06-15 |
Æterna Zentaris GmbH |
Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
|
|
CA2829790C
(en)
|
2010-03-30 |
2018-06-05 |
Verseon Corporation |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
|
WO2011146591A1
(en)
|
2010-05-19 |
2011-11-24 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
|
JP5894980B2
(ja)
|
2010-05-24 |
2016-03-30 |
インテリカイン， エルエルシー |
複素環式化合物およびその使用
|
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
|
CN102532141A
(zh)
|
2010-12-08 |
2012-07-04 |
中国科学院上海药物研究所 |
[1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
|
|
AU2012213080B2
(en)
|
2011-01-31 |
2014-03-27 |
Novartis Ag |
Novel heterocyclic derivatives
|
|
US20140037642A1
(en)
*
|
2011-02-02 |
2014-02-06 |
Amgen Inc. |
Methods and compositions relating to inhibition of igf-1r
|
|
CA2828483A1
(en)
|
2011-02-23 |
2012-11-01 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
|
WO2012118492A1
(en)
|
2011-03-01 |
2012-09-07 |
Array Biopharma Inc. |
Heterocyclic sulfonamides as raf inhibitors
|
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
|
|
EP2727042B1
(en)
*
|
2011-07-01 |
2016-04-06 |
Fiberlink Communications Corporation |
Rules based actions for mobile device management
|
|
US9295671B2
(en)
|
2011-08-26 |
2016-03-29 |
Neupharma, Inc. |
Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
|
|
US9518029B2
(en)
|
2011-09-14 |
2016-12-13 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
EP2757885B1
(en)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
|
WO2013052699A2
(en)
|
2011-10-04 |
2013-04-11 |
Gilead Calistoga Llc |
Novel quinoxaline inhibitors of pi3k
|
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
|
PL2771342T3
(pl)
|
2011-10-28 |
2016-11-30 |
|
Nowe pochodne puryny i ich zastosowanie w leczeniu chorób
|
|
HK1205528A1
(en)
|
2012-03-08 |
2015-12-18 |
Astellas Pharma Inc. |
Novel fgfr3 fusion product
|
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
US20150203589A1
(en)
|
2012-07-24 |
2015-07-23 |
The Trustees Of Columbia University In The City Of New York |
Fusion proteins and methods thereof
|
|
AU2014207342C1
(en)
|
2013-01-18 |
2019-04-04 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
|
CN105683197B
(zh)
|
2013-08-02 |
2019-12-27 |
亚尼塔公司 |
单独地或与其它试剂联合地使用AXL/cMET抑制剂治疗多种癌症的方法
|
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
|
BR112016022062B1
(pt)
|
2014-03-26 |
2023-04-11 |
Astex Therapeutics Limited |
Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico
|
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
|
EP3122358B1
(en)
|
2014-03-26 |
2020-12-16 |
Astex Therapeutics Ltd. |
Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
|
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
|
CA2976638A1
(en)
|
2015-02-19 |
2016-08-25 |
Bioclin Therapeutics, Inc. |
Methods, compositions, and kits for treatment of cancer
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|